Company: BGLC
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001477932-25-007976
Chunk: 17

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-07
Form: S-3
Chunk 17
---
 agreement for a series of warrants without the consent of the holders of the warrants issued thereunder to effect changes that are not inconsistent with the provisions of the warrants and that do not materially and adversely affect the interests of the holders of the warrants.

Prior to exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive distributions or dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise any voting rights.

| 10 |

<div align='center'>DESCRIPTION OF RIGHTS</div>

The following description, together with the additional information we include in any applicable prospectus supplement, summarizes the general features of the rights that we may offer under this prospectus. We may issue rights to our stockholders to purchase shares of our common stock and/or any of the other securities offered hereby. Each series of rights will be issued under a separate rights agreement to be entered into between us and a bank or trust company, as rights agent. When we issue rights, we will provide the specific terms of the rights and the applicable rights agreement in a prospectus supplement. Because the terms of any rights we offer under a prospectus supplement may differ from the terms we describe below, you should rely solely on information in the applicable prospectus supplement if that summary is different from the summary in this prospectus. We will incorporate by reference into the registration statement of which this prospectus is a part the form of rights agreement that describes the terms of the series of rights we are offering before the issuance of the related series of rights. The applicable prospectus supplement relating to any rights will describe the terms of the offered rights, including, where applicable, the following:

| ● | the date for determining the persons entitled to participate in the rights distribution;                                                      |
| ● | the exercise price for the rights;                                                                                                            |
| ● | the aggregate number or amount of underlying securities purchasable upon exercise of the rights;                                              |
| ● | the number of rights issued to each stockholder and the number of rights outstanding, if any;                                                 |
| ● | the extent to which the rights are transferable;                                                                                              |
| ● | any conditions to completing the rights offering;                                                                                             |
| ● | the date on which the right to exercise the rights will commence and the date on which the right will expire;                                 |
| ● | the extent to which the rights include an over-subscription privilege with respect to unsubscribed securities;                                |
| ●